{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T09:31:09Z","timestamp":1763458269149,"version":"3.44.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.transproceed.2023.07.011","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T07:38:11Z","timestamp":1693553891000},"page":"1784-1792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tixagevimab-Cilgavimab Decreases\u00a0the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients"],"prefix":"10.1016","volume":"55","author":[{"given":"Ava M.","family":"Sanayei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Montalvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Ochalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbra M.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn D.","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Curry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7157-5827","authenticated-orcid":false,"given":"Behnam","family":"Saberi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2023.07.011_bib0001","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0002","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/ajt.16424","article-title":"Is COVID-19 infection more severe in kidney transplant recipients?","volume":"21","author":"Caillard","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0003","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jinf.2021.01.022","article-title":"COVID-19 in immunocompromised patients: a systematic review of cancer, hematopoietic cell and solid organ transplant patients","volume":"82","author":"Belsky","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0004","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1097\/TP.0000000000004341","article-title":"Excess mortality among solid organ transplant recipients in the United States during the COVID-19 pandemic","volume":"106","author":"Clarke","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.6822","article-title":"Immunogenicity and risk factors associated with poor humoral immune response of SARS-CoV-2 vaccines in recipients of solid organ transplant: a systematic review and meta-analysis","volume":"5","author":"Manothummetha","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0006","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/tri.14029","article-title":"SARS-CoV-2 vaccination in solid-organ transplant recipients: what the clinician needs to know","volume":"34","author":"Giannella","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0007","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1111\/ajt.16541","article-title":"Prevalence and predictors of SARS-CoV-2 antibodies among solid organ transplant recipients with confirmed infection","volume":"21","author":"Burack","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0008","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0009","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMc2111462","article-title":"Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients","volume":"385","author":"Hall","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0010","unstructured":"Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19, <https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html>; 2021 [accessed 02.02.2023]."},{"key":"10.1016\/j.transproceed.2023.07.011_bib0011","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jama.2021.24931","article-title":"Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19","volume":"327","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0012","doi-asserted-by":"crossref","first-page":"eabl8124","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0013","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0014","unstructured":"Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab), <https:\/\/www.fda.gov\/media\/154701\/download>; 2021 [accessed 02.02.2023]."},{"key":"10.1016\/j.transproceed.2023.07.011_bib0015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0016","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/ajt.17121","article-title":"Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients","volume":"22","author":"Benotmane","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0017","unstructured":"Center for Drug Evaluation, Research. FDA announces Evusheld is not currently authorized for emergency use in the U.S. U.S. Food and Drug Administration, <https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us>; 2022 [accessed 02.02.2023]."},{"key":"10.1016\/j.transproceed.2023.07.011_bib0018","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1111\/ajt.17128","article-title":"Tixagevimab\/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave","volume":"22","author":"Al Jurdi","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0019","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0021","unstructured":"CDC. COVID data tracker weekly review, <https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/covid-data\/covidview\/index.html>; 2023 [accessed 02.04.2023]."},{"key":"10.1016\/j.transproceed.2023.07.011_bib0022","doi-asserted-by":"crossref","first-page":"e13772","DOI":"10.1111\/tid.13772","article-title":"Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls","volume":"24","author":"Yanis","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0023","first-page":"s12","article-title":"An overview of immunosuppression in solid organ transplantation","volume":"21","author":"Enderby","year":"2015","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.transproceed.2023.07.011_bib0024","unstructured":"Study Understanding Pre-Exposure Prophylaxis of Novel Antibodies (SUPERNOVA) - Full Text View - ClinicalTrials.Gov, <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05648110?term=SUPERNOVA&recrs=ab&draw=2&rank=1>; 2022 [accessed 02.02.2023]."}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113452300475X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113452300475X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:47:09Z","timestamp":1758577629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113452300475X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S004113452300475X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.07.011","relation":{},"ISSN":["0041-1345"],"issn-type":[{"type":"print","value":"0041-1345"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tixagevimab-Cilgavimab Decreases\u00a0the Rate of SARS-CoV-2 Infection Among Solid Organ Transplant Recipients","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}